Literature DB >> 8398693

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.

L D Skarsgard1, M W Skwarchuk, A Vinczan, D J Chaplin.   

Abstract

We have observed that low pH can substantially potentiate the cytotoxic effect of the bioreductive drug SR4233 in aerobic HT-29 human tumour cells. No such potentiation was observed under hypoxic conditions. This pH effect might be relevant both to the therapeutic effectiveness and to the normal tissue toxicity of this new agent.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8398693      PMCID： PMC1968590          DOI： 10.1038/bjc.1993.409

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents.

Authors:  P G Braunschweiger; S A Jones; C S Johnson; P Furmanski
Journal:  Int J Radiat Biol       Date:  1991 Jul-Aug       Impact factor: 2.694

2.  DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.

Authors:  J H Tocher; N S Virk; D I Edwards
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

3.  Pre- and post-irradiation radiosensitization by SR 4233.

Authors:  E M Zeman; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-04       Impact factor: 7.038

4.  Intermittent blood flow in a murine tumor: radiobiological effects.

Authors:  D J Chaplin; P L Olive; R E Durand
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

5.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.

Authors:  E M Zeman; J M Brown; M J Lemmon; V K Hirst; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

6.  Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity.

Authors:  M A Baker; E M Zeman; V K Hirst; J M Brown
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

7.  Acute hypoxia in tumors: implications for modifiers of radiation effects.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

8.  Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233).

Authors:  K Laderoute; P Wardman; A M Rauth
Journal:  Biochem Pharmacol       Date:  1988-04-15       Impact factor: 5.858

9.  Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.

Authors:  J M Brown; M J Lemmon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-03       Impact factor: 7.038

10.  Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma.

Authors:  J R Sun; J M Brown
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701
View more
  2 in total

1.  Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Authors:  Bo Hong; Vivian W Y Lui; Edwin P Hui; Margaret H L Ng; Suk-Hang Cheng; Fion L Sung; Chi-Man Tsang; Sai-Wah Tsao; Anthony Tak-Cheung Chan
Journal:  Invest New Drugs       Date:  2009-12-16       Impact factor: 3.850

2.  Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.

Authors:  Eugene Y Kim; Yanfeng Liu; Oluwatoyin M Akintujoye; Krishnamurthy Shyam; Tina A Grove; Alan C Sartorelli; Sara Rockwell
Journal:  Radiat Res       Date:  2012-08-03       Impact factor: 2.841
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.